Abstract
Introduction and hypothesis
Patients with overactive bladder (OAB) become discouraged with medication therapy because of the side effects, minimal subjective improvement and costs of therapy. With the implementation of a patient navigation pathway there is increased communication, subsequently leading to increased patient retention rates and utilization of third-line therapies.
Methods
This was a quality improvement study carried out over a 17-month period comparing utilization of a navigation pathway versus patients without navigation. The data were obtained using an online database (PPS Analytics) to compare medication use, cystoscopy, urodynamic studies, use of third-line therapy, and return visits.
Results
A total of 535 patients were included in the analysis and broken down into two respective groups. Group 1 were those placed on the navigation pathway and able to be reached via telephone (n = 431). Group 2 were those started on the navigation pathway who were not able to be reached via telephone, but were chart reviewed by a navigator (n = 104). Third-line therapy usage for groups 1 and 2 was 24% and 11% respectively. Return visits for additional OAB management for groups 1 and 2 were found to be 71% and 50% respectively.
Conclusion
Patient retention levels and utilization of third-line therapies are significantly improved when utilizing a navigation pathway. With 24% of the patients included in this study opting for third-line therapy, this represents a 600% increase in third-line therapies over national averages.
Similar content being viewed by others
Abbreviations
- AUA:
-
American Urological Association
- FPMRS:
-
Female pelvic medicine and reconstructive surgery
- OAB:
-
Overactive bladder
- SUFU:
-
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction
- UDS:
-
Urodynamic studies
References
Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29:4–20.
Stewart W, Herzog R, Wein A, et al. The prevalence and impact of overactive bladder in the U.S.: results from the NOBLE program. Neurourol Urodyn. 2001;20:406–8.
Gormley EA, Lightner DJ, Faraday M, Vasavada SP; American Urological Association; Society of Urodynamics, Female Pelvic Medicine. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015;193:1572–80.
Zimmern P, Litman HJ, Mueller E, Norton P, Goode P. Effect of fluid management on fluid intake and urge incontinence in a trial for overactive bladder in women. BJU Int. 2010;105(12):1680–5.
Sexton CC, Notte SM, Maroulis C, et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract. 2011;65(5):567–85.
Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health. 2005;8(4):495–505.
Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728–40.
Hartigan S, Fischer K, Wein A, Jaffe W. High attrition rate and low progression to advanced therapy for patients with overactive bladder: a hospital system wide study. Neurourol Urodyn. 2018;37(Suppl 1):S576–7.
Lloyd J, Guzman J, Giusto L, et al. Trends in third line therapy utilization for overactive bladder amongst general urologists, advanced practice providers, and FPMRS subspecialists. Neurourol Urodyn. 2018;37(Suppl 1):S584.
Knight JC. Practitioner application: the impact of patient navigation on diabetes. J Healthc Manag. 2018;63(3):e41–2.
English TM, Masom D, Whitman MV. The impact of patient navigation on diabetes. J Healthc Manag. 2018;63(3):e32–41.
Serrell EC, Hansen M, Mills G, et al. Prostate cancer navigation: initial experience and association with time to care. World J Urol 2018. 2019;37(6):1095–1101.
Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000;6(Suppl):S580–90.
Nitti V. Clinical impact of overactive bladder. Rev Urol. 2002;4(Suppl 4):S2–6.
Milsom I, Abrams P, Cardoza L, et al. How widespread are the symptoms of overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87:760–6.
Schabert VF, Bavendam T, Goldberg EL, Trocio JN, Brubaker L. Challenges for managing overactive bladder and guidance for patient support. Am J Manag Care. 200915 (4 Suppl):S118–22.
Moskowitz D, Adelstein SA, Lucioni A, Lee UJ, Kobashi KC. Use of third line therapy for overactive bladder in a practice with multiple subspecialty providers—are we doing enough? J Urol. 2018;199(3):779–84.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
There are no conflicts of interest in the publication of this article.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Rohloff, M., Peifer, G. & Thompson, J.H. Patient navigation for overactive bladder improves access to care. Int Urogynecol J 31, 1007–1012 (2020). https://doi.org/10.1007/s00192-019-04085-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00192-019-04085-7